Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) Stock Price

ARCTStock

$10.34−52.42%52W

Market Cap$293.89M

P/E—

PEG Ratio—

Div yield—

Beta2.62

ARCT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)9.22%

Price vs S&P 500 (4W)-28.29%

VGM Score54.01

Book Value / Share (Quarterly)$6.04

P/TBV (Annual)2.36x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-26.43%

Cash Flow / Share (Quarterly)$-2.56

Price vs S&P 500 (YTD)56.75%

Net Profit Margin (TTM)-317.62%

EPS (TTM)$-3.31

10-Day Avg Trading Volume0.69M

EPS Excl Extra (TTM)$-3.31

Revenue Growth (5Y)53.90%

EPS (Annual)$-2.40

ROI (Annual)-30.74%

Net Profit Margin (5Y Avg)-357.81%

Cash / Share (Quarterly)$6.74

Revenue Growth QoQ (YoY)-89.54%

ROA (Last FY)-24.26%

Revenue Growth TTM (YoY)-75.95%

EBITD / Share (TTM)$-3.55

ROE (5Y Avg)-32.16%

Operating Margin (TTM)-348.33%

Cash Flow / Share (Annual)$-2.62

P/B Ratio1.71x

P/B Ratio (Quarterly)1.11x

Net Income / Employee (Annual)$-620,600

EV / Revenue (TTM)3.49x

Net Interest Coverage (TTM)8.07x

ROA (TTM)-36.46%

EV / EBITDA (TTM)1.04x

EPS Incl Extra (Annual)$-2.40

Current Ratio (Annual)6.64x

Quick Ratio (Quarterly)5.76x

3-Month Avg Trading Volume0.82M

52-Week Price Return-52.42%

EV / Free Cash Flow (Annual)97.69x

Revenue / Employee (TTM)$277,000

Tangible BV / Share (Quarterly)$10.48

P/S Ratio (Annual)3.58x

Asset Turnover (Annual)0.30x

52-Week High$24.17

Operating Margin (5Y Avg)-362.44%

EPS Excl Extra (Annual)$-2.40

CapEx CAGR (5Y)-33.28%

Tangible BV CAGR (5Y)51.57%

26-Week Price Return19.12%

Quick Ratio (Annual)6.50x

13-Week Price Return70.91%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.88x

Enterprise Value$102.41M

Revenue / Share Growth (5Y)44.96%

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-13.03%

Revenue / Employee (Annual)$773,900

Pretax Margin (Annual)-80.19%

Cash / Share (Annual)$8.13

3-Month Return Std Dev110.94%

Net Income / Employee (TTM)$-880,000

ROE (Last FY)-30.74%

Net Interest Coverage (Annual)19.72x

EPS Basic Excl Extra (Annual)$-2.40

P/FCF (TTM)1.42x

Receivables Turnover (TTM)3.09x

EV / Free Cash Flow (TTM)3.61x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.31

Receivables Turnover (Annual)17.20x

ROI (TTM)-46.54%

P/S Ratio (TTM)10.01x

Pretax Margin (5Y Avg)-357.47%

Revenue / Share (Annual)$3.00

Tangible BV / Share (Annual)$10.18

Price vs S&P 500 (52W)-67.95%

Year-to-Date Return68.68%

5-Day Price Return-18.00%

EPS Normalized (Annual)$-2.40

ROA (5Y Avg)-20.90%

Net Profit Margin (Annual)-80.19%

Month-to-Date Return-24.47%

Cash Flow / Share (TTM)$3.73

EBITD / Share (Annual)$-2.67

Operating Margin (Annual)-92.96%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-28.42%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-3.31

P/TBV (Quarterly)2.28x

P/B Ratio (Annual)0.81x

Pretax Margin (TTM)-317.64%

Book Value / Share (Annual)$7.53

Price vs S&P 500 (13W)68.22%

Beta2.62x

P/FCF (Annual)12.11x

Revenue / Share (TTM)$1.03

ROE (TTM)-46.54%

52-Week Low$5.50

vGradeB

gGradeD

mGradeC

vgmGradeC

ARCT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.03	-$0.84	+18.11%(+$0.19)
Q1 2026	May 7, 2026	-$1.01	-$0.95	+6.25%(+$0.06)
Q4 2025	Mar 3, 2026	-$0.76	-$1.03	-36.40%(-$0.27)
Q3 2025	Nov 10, 2025	-$0.80	-$0.49	+38.71%(+$0.31)
Q2 2025	Aug 11, 2025	-$0.85	-$0.34	+59.81%(+$0.51)

ARCT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.06

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ARCTArcturus Therapeutics Holdings Inc. Common Stock	B	D	C	10.0x	-76.0%	—	—	$10.34
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Arcturus Therapeutics Holdings Inc. Common Stock

Arcturus Therapeutics develops mRNA medicines focused on infectious disease vaccines and rare liver and respiratory disease therapies. Its pipeline includes vaccine candidates for influenza and COVID-19 variants, as well as programs for rare genetic conditions. The company aims to address significant unmet medical needs in high-value therapeutic areas.

ARCT Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.68

Revenue estimate$8.04M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

CGCCanopy Growth Corporation Common SharesPharmaceutical Preparations
SNDLSundial Growers Inc. Common SharesPharmaceutical Preparations
OECOrion S.A.Industrial Chemicals
GLASGlass House Brands Inc.Pharmaceutical Preparations
GEVOGevo, Inc.Industrial Chemicals
USNAUSANA Health Sciences IncPharmaceutical Preparations
ARTVArtiva Biotherapeutics, Inc. Common StockBiological Products
SRZNSurrozen, Inc. CommonBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$5.50

High$24.17